Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial

Introduction Uterine serous carcinoma (USC) accounts for 40% of endometrial cancer-related deaths. The standard of care for stages III and IV USC yields a 20%–30% survival at 2 years and a 10%–20% survival at 3–5 years. Recent advances in the second-line treatment of advanced or recurrent USC are ra...

Full description

Bibliographic Details

Published in:	BMJ Open
Main Authors:	Gary L Goldberg, Jeannine Villella, Natalie Danziger, Joan Tymon-Rosario, Eugenia Girda, Marina Frimer, Veena John, Fidel Valea, Andrew Menzin, Lisa Dos Santos, Arielle Katcher, Pegah Blustein, Cristina Sison, Aaron Nizam, Lauren Scanlon, Jill S Whyte, Antoinette Sakaris, Elena Pereira, Yi-shin D Kuo, Jean Lee, Marisa Siebel, Julia Elvin, Karin Shih
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-06-01
Online Access:	https://bmjopen.bmj.com/content/15/6/e087115.full